Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
FibroGen, Inc. FGEN
$17.32
-$0.28 (-1.59%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1704734684.00000000
-
week52high
25.69
-
week52low
8.15
-
Revenue
140734000
-
P/E TTM
-6
-
Beta
0.79896100
-
EPS
-3.05000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| Goldman Sachs | Sell | Sell | 01 мар 2022 г. |
| Goldman Sachs | Sell | Neutral | 22 сент 2021 г. |
| Raymond James | Market Perform | Underperform | 20 авг 2021 г. |
| SVB Leerink | Outperform | Outperform | 10 авг 2021 г. |
| Goldman Sachs | Sell | Sell | 08 ноя 2022 г. |
| B of A Securities | Buy | Neutral | 05 янв 2023 г. |
| William Blair | Outperform | Market Perform | 31 янв 2023 г. |
| Raymond James | Outperform | Market Perform | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Conterno Enrique A | D | 295483 | 1538 | 06 янв 2023 г. |
| Wettig Thane | D | 89163 | 734 | 23 дек 2022 г. |
| Graham Juan | D | 47962 | 1407 | 12 дек 2022 г. |
| Graham Juan | D | 53703 | 1407 | 12 дек 2022 г. |
| Graham Juan | D | 49369 | 781 | 09 дек 2022 г. |
| Graham Juan | D | 55110 | 781 | 09 дек 2022 г. |
| Chung Christine | D | 234873 | 2595 | 08 дек 2022 г. |
| Graham Juan | D | 50150 | 478 | 08 дек 2022 г. |
| Graham Juan | D | 50628 | 5263 | 08 дек 2022 г. |
| Conterno Enrique A | D | 297020 | 2543 | 08 дек 2022 г. |
Новостная лента
FibroGen, Inc. (FGEN) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 23:14
FibroGen, Inc. (NASDAQ:FGEN ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Michael Tung - Vice President, Corporate Strategy & Investor Relations Enrique Conterno - Chief Executive Officer Juan Graham - Chief Financial Officer Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Paul Choi - Goldman Sachs Michael Yee - Jefferies Annabel Samimy - Stifel Yaron Werber - Cowen Operator Good day, and thank you for standing by. Welcome to FibroGen's First Quarter 2023 Earnings Call.
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:03
FibroGen (FGEN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.68 per share a year ago.
FibroGen to Report First Quarter 2023 Financial Results
GlobeNewsWire
24 апр 2023 г. в 07:00
SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
FibroGen: Despite Some Progress, Roxadustat's Data Disaster Still Haunts It
Seeking Alpha
29 мар 2023 г. в 14:15
FibroGen, Inc. got roxa approved in the EU and China, but not in the U.S. The data manipulation problem from two years ago still haunts FibroGen, Inc.
FibroGen, Inc. (FGEN) Q4 2022 Earnings Call Transcript
Seeking Alpha
27 февр 2023 г. в 22:59
FibroGen, Inc. (NASDAQ:FGEN ) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Michael Tung - VP of Corporate Strategy and IR Enrique Conterno - CEO Mark Eisner - Chief Medical Officer Juan Graham - CFO Thane Wettig - Chief Commercial Officer Conference Call Participants Andrew Tsai - Jefferies Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Yaron Werber - Cowen Annabel Samimy - Stifel Operator Thank you for standing by, and welcome to FibroGen's Fourth Quarter and Full Year 2022 Financial Results Earnings Call. [Operator Instructions].